Valuation dashboard for Avantor, Inc. (AVTR) with P/E 32.05, P/B 1.86, EV/EBITDA 15.50 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises.
Analysis Summary
Avantor, Inc. reported revenue of $6.55B in the most recent fiscal year, growing at a 5-year CAGR of 0.5%.
Trailing-twelve-month margins: gross margin 31.6%, operating margin 7.6%, net margin 5.1%.
At $16.05 (closing price, October 30, 2026), AVTR trades at a P/E of 32.05 and an ROE of 5.96%. Market capitalisation stands at $10.9B, placing it among large-cap names.
Balance sheet quality for AVTR: current ratio of 1.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 32.05 |
| Price / Book | 1.86 |
| EV / EBITDA | 15.50 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $19.34 |
| vs Current Price | +20.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AVTR | Avantor, Inc. | $10.9B | 32.05 | 1.86 | 6.0% |
| RGEN | Repligen Corporation | $11.2B | 4.78 | -0.6% | |
| DHR | Danaher Corporation | $163.3B | 38.01 | 3.05 | 8.2% |
| WST | West Pharmaceutical Services, Inc. | $28.7B | 46.31 | 9.79 | 21.1% |
| CRL | Charles River Laboratories International, Inc. | $17.3B | 6.14 | -7.7% | |
| BIO | Bio-Rad Laboratories, Inc. | $10.0B | 45.11 | 1.39 | 3.2% |
| STVN | Stevanato Group S.p.A. | $5.3B | 36.10 | 3.05 | 8.9% |
Price
| Price | $16.05 (closing price, October 30, 2026) |
| Market Cap | $10.9B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 5.96% |
| Return on Invested Capital | 4.88% |
| Return on Assets | 2.90% |
| Gross Margin | 31.59% |
| Operating Margin | 7.58% |
| Net Margin | 5.08% |
Related companies: RGEN · DHR · WST · CRL · BIO · STVN
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of AVTR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks